CI
ALNY icon

Cordant Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cordant Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223 Buy
+1
New +$302 ﹤0.01% 266
2022
Q2 		– Sell
-4
Closed -$1K – 109
2022
Q1 		$1K Buy
+4
New +$609 ﹤0.01% 843
2021
Q4 		– Sell
-4
Closed -$1K – 88
2021
Q3 		$1K Buy
+4
New +$750 ﹤0.01% 206

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cordant Inc's ALNY Position: Q2 2026 in Review

Cordant Inc opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 1 share worth $223. The stake represents ﹤0.01% of the portfolio and ranks #266 among its holdings. This is a return to the name: Cordant Inc previously reported a position in ALNY as recently as Q1 2022.

Cordant Inc first reported a position in ALNY in Q3 2021 and has held it in 3 quarters since. The position peaked at $1K in Q1 2022. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Cordant Inc held 1 share of Alnylam Pharmaceuticals worth $223 as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Cordant Inc position in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Cordant Inc's portfolio in Q2 2026, its #266 holding.
  • Cordant Inc first reported a position in Alnylam Pharmaceuticals in Q3 2021 and has held it in 3 quarters since.
  • Cordant Inc's Alnylam Pharmaceuticals position peaked at $1K in Q1 2022.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cordant Inc's 13F filing for Q2 2026, filed 15 Jul 2026.